Vizgen, a Cambridge, Mass.-based life science company dedicated to advancing human health by visualizing single-cell spatial genomics information, closed a $37m Series B financing.
The round was co-led by Novalis LifeSciences LLC, and current investor Northpond Ventures with participation from new investors Tao Capital Partners, Pura Vida Investments, LLC, and a large U.S. endowment fund, and current investors ARCH Venture Partners and David Walt, Ph.D., Professor at Harvard Medical School, Core Faculty at the Wyss Institute, and co-founder of Vizgen. Joining Vizgen’s Board of Directors is Marijn Dekkers, Ph.D., Chairman and Founder of Novalis LifeSciences LLC, an investment and advisory firm for the life science industry. Dekkers brings over three decades of life science industry experience to support the Vizgen team, having previously served as CEO of Bayer AG and Thermo Fisher Scientific. In 2019, Dekkers was named Chairman of the Board of Ginkgo Bioworks.
The company intends to use the funds to accelerate growth and infrastructure expansion leading up to full commercial launch.
Led by Terry Lo, President and CEO, Vizgen is developing genomic profiling tools that enable researchers to gain new insight into the biological systems that underlie human health and disease with spatial context. The company’s MERSCOPETM platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution.
FinSMEs
07/04/2021